Lipoprotein(a) Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting lipoprotein(a) clinical trials across 38 countries. Studies span Not Applicable, Phase 3. Top locations include Budapest, Hungary, Lodz, Poland, Amsterdam, North Holland, Netherlands. Updated daily from ClinicalTrials.gov.


Lipoprotein(a) Trials at a Glance

7 actively recruiting trials for lipoprotein(a) are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Budapest, Lodz, and Amsterdam. Lead sponsors running lipoprotein(a) studies include E.S.stroes, Novartis Pharmaceuticals, and China National Center for Cardiovascular Diseases.

Browse lipoprotein(a) trials by phase

Treatments under study

About Lipoprotein(a) Clinical Trials

Looking for clinical trials for Lipoprotein(a)? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lipoprotein(a) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lipoprotein(a) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting

Lipid Screening Study

Lipoprotein(a)
University of Central Florida30 enrolled1 locationNCT07579325
Recruiting

AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)

AI (Artificial Intelligence)BiomarkersMyocardial Ischemia+4 more
University of Galway10,000 enrolled1 locationNCT07577609
Recruiting

Cardiovascular Risk in Children With Chronic Conditions Study

Obesity and OverweightLymphomaLeukemia+22 more
Semmelweis University300 enrolled3 locationsNCT07086989
Recruiting
Not Applicable

24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

Coronary Artery DiseaseDrug-eluting StentDual Antiplatelet Therapy+1 more
China National Center for Cardiovascular Diseases3,300 enrolled1 locationNCT06014060
Recruiting

Heart CT Imaging to Detect Early Coronary Artery Disease in First-Degree Relatives With High or Low Lipoprotein(a) Identified Through Family Screening

Lipoprotein(a)
E.S.stroes150 enrolled1 locationNCT06995183
Recruiting

The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry

Lipoprotein(a), Hyper-Lp(a)-Emia
Polish Mother Memorial Hospital Research Institute2,000 enrolled1 locationNCT06610669